Armata Pharmaceuticals (ARMP) Net Income towards Common Stockholders (2016 - 2018)
Historic Net Income towards Common Stockholders for Armata Pharmaceuticals (ARMP) over the last 6 years, with Q4 2018 value amounting to -$8.9 million.
- Armata Pharmaceuticals' Net Income towards Common Stockholders fell 28248.93% to -$8.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$13.6 million, marking a year-over-year increase of 560.57%. This contributed to the annual value of -$53.2 million for FY2024, which is 2270.81% down from last year.
- Latest data reveals that Armata Pharmaceuticals reported Net Income towards Common Stockholders of -$8.9 million as of Q4 2018, which was down 28248.93% from -$1.6 million recorded in Q3 2018.
- In the past 5 years, Armata Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $14.5 million in Q3 2014 and a low of -$14.8 million during Q1 2015
- In the last 5 years, Armata Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$3.2 million in 2015 and averaged -$2.7 million.
- Over the last 5 years, Armata Pharmaceuticals' Net Income towards Common Stockholders had its largest YoY gain of 16367.15% in 2014, and its largest YoY loss of 60644.38% in 2014.
- Over the past 5 years, Armata Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$994000.0 in 2014, then crashed by 219.92% to -$3.2 million in 2015, then tumbled by 198.74% to -$9.5 million in 2016, then surged by 75.47% to -$2.3 million in 2017, then tumbled by 282.49% to -$8.9 million in 2018.
- Its Net Income towards Common Stockholders stands at -$8.9 million for Q4 2018, versus -$1.6 million for Q3 2018 and -$3.0 million for Q2 2018.